Literature DB >> 4111245

Treatment of myasthenia gravis with prednisone.

R B Jenkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4111245     DOI： 10.1016/s0140-6736(72)90520-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

Review 2.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

3.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

Review 4.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

Review 5.  Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Authors:  Deepak Menon; Vera Bril
Journal:  Drugs       Date:  2022-05-31       Impact factor: 11.431

6.  Immune regulation of experimental myasthenia.

Authors:  S Fuchs; D Bartfeld; Z Eshhar; C Feingold; D Mochly-Rosen; D Novick; M Schwartz; R Tarrab-Hazdai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

7.  The in vivo effects of corticosteroids on thymocyte subsets in myasthenia gravis.

Authors:  S Berrih; D Safar; P Levasseur; C Gaud; J F Bach
Journal:  J Clin Immunol       Date:  1984-03       Impact factor: 8.317

8.  Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.

Authors:  Laura Díez-Porras; Christian Homedes; Maria Antonia Alberti; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.